Immune suppression is a known risk
factor for developing lymphomas. It's also a known consequence of disease
progression and a common side effect of standard treatments.
{beta}2-microglobulin
-[associated with NHL progression] as a negative regulator
of the immune system: high concentrations of the protein inhibit
in vitro generation of functional dendritic cells.
Blood. 2003 Jan
16 PMID: 12531797
PubMed
Th1/Th2 cytokine expression and its relationship with tumor
growth in B cell non-Hodgkin's lymphoma (NHL).
Leuk Lymphoma. 2002
Jun;43(6):1313-21.
PMID: 12153001
PubMed
The Prevalence of Blastocystis Hominis in Immunosuppressed
Patients ams.cu.edu.tr
Treatment-related immune
suppression
Pure red cell aplasia due to parvovirus following treatment
with CHOP and rituximab for B-cell lymphoma.
Br J Haematol. 2002
Oct;119(1):125-7. PMID: 12358915
PubMed
Frequency and type of serious infections in
Fludarabine-refractory B-cell chronic lymphocytic leukemia and
small lymphocytic lymphoma: implications for clinical trials in
this patient population. Cancer. 2002 Apr 1;94(7):2033-9. PMID:
11932906
PubMed
Epstein-Barr virus-positive B-cell lymphoproliferative
disorders arising in immunodeficient patients previously treated
with fludarabine for low-grade B-cell neoplasms.
Am J Surg Pathol.
2002 May;26(5):630-6. PMID: 11979093
PubMed
Infection-
related Immune-dysfunction
B-cell lymphomas involving the skin associated with hepatitis
C virus infection. Int J Dermatol. 2002 Sep;41(9):577-82. PMID:
12358827 - PubMed
.gif){kind=small}